Cervarix targets HPV types 16 and 18. It's approved for females aged 10-25 to help prevent cervical cancer. Both are relatively new vaccines-- the FDA approved Gardasil in 2006 and Cervarix in 2009.

September 11, 2009 — A second vaccine against human papillomavirus (HPV) for the prevention of cervical cancer — GlaxoSmithKline's Cervarix — has been recommended for approval in the United ...

"Even though it can be a difficult thing to talk about." There are two HPV vaccines: Gardasil and Cervarix. Cervarix guards against two HPV types (16 and 18). It's indicated to help prevent ...

Until 2012, the vaccine in use was the bivalent Cervarix, targeting HPV 16 and 18. Then the quadrivalent Gardasil was administered until 2023, when the nonavalent Gardasil 9 was introduced.

The British study involved a vaccine called Cervarix, that protects against two variants of the virus. The current American version of the HPV vaccine, called Gardasil-9, is even more effective ...

The next HPV vaccine approved in the United States, called Cervarix, is a bivalent vaccine that protects against HPV types 16 ...

Merck & Co's (MRK.N), opens new tab quadrivalent vaccine Gardasil, which protects against four HPV types linked to cervical and head and neck cancers, has been used in England instead of Cervarix.

September 30, 2009 (updated October 1, 2009) — The sudden death of a 14-year-old British girl shortly after she received Cervarix, a vaccine against human papillomavirus (HPV) to prevent ...

The HPV vaccines Gardasil and Cervarix have received their fair share of controversy since their approval by the U.S. Food and Drug Administration in 2006 and 2009, respectively. The Centers for ...

The two approved vaccines, Gardasil and Cervarix, are designed to protect ... Cervical Cancer Many find the public health case for HPV vaccination compelling. Cervical cancer strikes about 12,000 ...

One dose of a human papillomavirus (HPV) vaccine was noninferior to two doses in preventing infection, data from a randomized trial showed. In the ESCUDDO trial, which involved more than 20,000 ...

With a second brand approved and recommendations for immunizing boys, the HPV vaccine is back in the headlines, sparking new questions and the same old debate.